MARKET

OBIO

OBIO

Orchestra BioMed Holdings Inc
NASDAQ
5.70
+0.02
+0.35%
After Hours: 5.88 +0.18 +3.16% 19:16 11/09 EST
OPEN
5.73
PREV CLOSE
5.68
HIGH
5.88
LOW
5.36
VOLUME
785.15K
TURNOVER
--
52 WEEK HIGH
6.50
52 WEEK LOW
3.460
MARKET CAP
435.78M
P/E (TTM)
-5.6492
1D
5D
1M
3M
1Y
5Y
1D
Orchestra BioMed Holdings, Inc. Closes $86.3 Million Public Offering of Common Stock
NASDAQ · 1h ago
Orchestra BioMed Completes $86.3 Million Public Offering
TipRanks · 5h ago
Weekly Report: what happened at OBIO last week (1102-1106)?
Weekly Report · 18h ago
U.S. Earnings Preview: After Market Close Nov. 6
Dow Jones · 3d ago
Orchestra BioMed's Earnings Timing Will Collide With Its Capital Raise, Or It Won't
Barchart · 3d ago
Orchestra BioMed 15M share Spot Secondary priced at $5.00
TipRanks · 3d ago
Orchestra BioMed Prices $75 Mln Offering At $5/Shr To Fund Pivotal Trials
NASDAQ · 3d ago
*Orchestra BioMed: To Use Remainder for Working Capital, Other General Purposes >OBIO
Dow Jones · 4d ago
More
About OBIO
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Webull offers Orchestra Biomed Holdings Inc stock information, including NASDAQ: OBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OBIO stock methods without spending real money on the virtual paper trading platform.